Societal CDMO (SCTL) 10-Q2021 Q1 Quarterly report

Filed: 6 May 21, 4:15pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accuracy, added, antidilutive, begun, Commission, complex, construction, convenience, dedicated, defense, delay, delayed, denied, dosage, doubtful, easing, exclusively, exposure, forecast, goal, joint, margin, NOL, onset, outcome, outlook, purpose, pursue, resolution, resolved, responded, retention, satisfactory, seek, solving, spun, standalone, strategy, substance, unamortized

Removed: accredited, accretion, agent, aggregated, allocation, assessing, assigned, assumed, bid, billed, bridge, BXRX, caption, carefully, charged, classified, close, closed, competitor, consisting, context, converted, convey, Corporation, Cowen, criteria, dated, deducting, description, determination, distributed, distributing, dividend, eligible, entering, ER, exceed, execution, expanded, expiration, expressed, feature, forfeited, Fractional, framework, govern, hold, implemented, improvement, incur, independent, integrated, IPO, Ireland, July, leading, limit, limited, line, longer, measure, methodology, obtained, occurrence, operation, original, outbreak, par, performed, preferred, preliminary, pro, range, rata, recast, Redeemable, refer, reflected, reimbursement, relate, relationship, remained, repayment, repricing, revaluation, saving, sell, single, sliding, slower, speak, stocking, strain, subsidiary, surrendering, symbol, termination, trade, trading, transferred, transition, unanticipated, underlying, understand, underwriting, underwritten, unforeseen, viewed, warrant, Zohydro

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Associated SCTL transcripts

SCTL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Recro Pharma, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer’s knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 6, 2021

/s/ J. David Enloe, Jr.

J. David Enloe, Jr.

President and Chief Executive Officer

(Principal Executive Officer)

/s/ Ryan D. Lake

Ryan D. Lake

Chief Financial Officer

(Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.